Faron Pharmaceuticals Oy

Juho Jalkanen

Markku Jalkanen

Matti Karvonen

Maija-Leena Hollmén

Alexander Spicer

Jami Mandelin

Felix Vaura

Reetta Virtakoivu

A method for preventing and/or treating systemic inflammatory response syndrome (SIRS), the method comprising administration of an agent capable of up-regulating CD73 in combination with a glucocorticoid and/or an agent capable of agonizing the glucocorticoid receptor, wherein an agent capable of up-regulating CD73 and a glucocorticoid and/or an agent capable of agonizing the glucocorticoid receptor are administered sequentially. An agent capable of up-regulating CD73 is administered prior to a glucocorticoid and/or an agent capable of agonizing the glucocorticoid receptor.

Treatment of diseases with sequential administration of an agent capable of up-regulating CD73 and glucocorticoids

A method for determining a patient's responsiveness to a therapy comprising administration of type I interferon in order to make the decision to treat a patient with type I interferon and use of a SNP rs9984273 (C/T) in IFNAR2 as a marker for determining a patient's responsiveness to said therapy.

Method for determining patient's responsiveness to type 1 interferon treatment and use of type 1 interferon to treat patient having specified single nucleoide polymophism

Growing community of inventors

Mietoinen, Finland

Juho Jalkanen